FDA States The Psychedelic Psilocybin is a ‘Breakthrough Therapy’ for Severe Depression

For the second time in a year, the U.S. Food and Drug Administration (FDA) has designated psilocybin therapy currently being tested in clinical trials as "breakthrough therapy," an action that is meant to accelerate the typically sluggish process of drug development and review.